Top ▲
This section gives an overview of the disease, and where available shows the following:
More information can be found in the help pages.
✖Disease ID: | 1054 | |
Name: | Ulcerative colitis | |
Associated with: | 3 targets | |
1 immuno-relevant target | ![]() |
|
24 immuno-relevant ligands |
Click on the target name to link to its detailed view page
Where available, information is display on the role of the target in the disease; drugs which target the disease and their therapeutic use and side-effects.
If there is mutation data curated in GtoPdb this is indicated, with a link back to the appropriate section on the target detailed view page
Immuno ligand interactions - If available, a table of immuno-relevant ligands is shown. These ligands have been curated as having an association to the disease and possess interaction data with the target in GtoPdb. The approval status of the ligand is shown, along with curator comments and an indication of whether the target is considered the primary target of the ligand.
More information can be found in the help pages.
✖TLR4 |
nucleotide binding oligomerization domain containing 2 |
heat shock protein family A (Hsp70) member 1 like | |
Comments: | Genetic mutations that cause amino acid changes in the HSPA1L protein have been identified in patients with UC. |
Click ligand name to view ligand summary page
Click the arrow in the final column to expand comments
More information can be found in the help pages.
✖Key to terms and symbols | Click ligand name to view ligand summary | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
1. Argollo M, Furfaro F, Gilardi D, Roda G, Allocca M, Peyrin-Biroulet L, Danese S. (2020) Modulation of sphingosine-1-phosphate in ulcerative colitis. Expert Opin Biol Ther, 20 (4): 413-420. [PMID:32093531]
2. BANGHART HE, WATANABE RK. (1956) Corticotropin-zinc hydroxide evaluation in the therapy of certain collagen diseases. Am Pract Dig Treat, 7 (12): 1957-62. [PMID:13372943]
3. Beidler CB, Bright SW, Girard DS, Kikly KK. (2015) Antibodies that bind to IL-23. Patent number: US9023358B2. Assignee: Eli Lilly and Co Ltd (GB). Priority date: 08/03/2013. Publication date: 05/05/2015.
4. Cerep. ExpresSProfile - P1. Accessed on 08/06/2015. Modified on 08/06/2015. http://www.cerep.fr, http://www.cerep.fr/cerep/users/pages/catalog/profiles/DetailProfile.asp?profile=2117
5. Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, Martin WH, Rizzuti BJ, Sawyer PS, Perry BD, Brissette WH et al.. (2003) Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science, 302 (5646): 875-8. [PMID:14593182]
6. Derfuss T, Mehling M, Papadopoulou A, Bar-Or A, Cohen JA, Kappos L. (2020) Advances in oral immunomodulating therapies in relapsing multiple sclerosis. Lancet Neurol, 19 (4): 336-347. [PMID:32059809]
7. Deshpande S, Huang H, Srinivasan M, Cardarelli JM, Wang C, Passmore DB, Rangan V, Lane TE, Keirstead HS, Liu MT. (2012) IP-10 antibodies and their uses. Patent number: US8258266 B2. Assignee: Medarex, Inc.. Priority date: 10/12/2003. Publication date: 04/09/2012.
8. Duggan S, Keam SJ. (2019) Upadacitinib: First Approval. Drugs, 79 (16): 1819-1828. [PMID:31642025]
9. Fleischmann R, Pangan AL, Song IH, Mysler E, Bessette L, Peterfy C, Durez P, Ostor AJ, Li Y, Zhou Y et al.. (2019) Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial. Arthritis Rheumatol, 71 (11): 1788-1800. [PMID:31287230]
10. Fong S, Dennis MS. (2009) Humanized anti-beta7 antagonists and uses therefor. Patent number: US7528236 B2. Assignee: Genentech, Inc.. Priority date: 03/09/2004. Publication date: 09/05/2009.
11. Giles-Komar J, Knight DM, Peritt D, Scallon B, Shealy D. (2005) Also an IL-12 anti-idiotype antibody to the antibody. Patent number: US6902734. Assignee: Centocor, Inc.. Priority date: 07/08/2000. Publication date: 07/06/2005.
12. Griggs RC, Miller JP, Greenberg CR, Fehlings DL, Pestronk A, Mendell JR, Moxley 3rd RT, King W, Kissel JT, Cwik V et al.. (2016) Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy. Neurology, 87 (20): 2123-2131. [PMID:27566742]
13. Harris PA, Berger SB, Jeong JU, Nagilla R, Bandyopadhyay D, Campobasso N, Capriotti CA, Cox JA, Dare L, Dong X et al.. (2017) Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases. J Med Chem, 60 (4): 1247-1261. [PMID:28151659]
14. Jones JE, Causey CP, Knuckley B, Slack-Noyes JL, Thompson PR. (2009) Protein arginine deiminase 4 (PAD4): Current understanding and future therapeutic potential. Curr Opin Drug Discov Devel, 12 (5): 616-27. [PMID:19736621]
15. Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, Hsia EC, Han J, Wagner C, Xu Z et al.. (2008) Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum, 58 (4): 964-75. [PMID:18383539]
16. Keam SJ. (2023) Mirikizumab: First Approval. Drugs, 83 (11): 1045-1052. [PMID:37389706]
17. Kennedy Crispin M, Ko JM, Craiglow BG, Li S, Shankar G, Urban JR, Chen JC, Cerise JE, Jabbari A, Winge MC et al.. (2016) Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight, 1 (15): e89776. [PMID:27699252]
18. King B, Zhang X, Harcha WG, Szepietowski JC, Shapiro J, Lynde C, Mesinkovska NA, Zwillich SH, Napatalung L, Wajsbrot D et al.. (2023) Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial. Lancet, 401 (10387): 1518-1529. [PMID:37062298]
19. Knuckley B, Luo Y, Thompson PR. (2008) Profiling Protein Arginine Deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors. Bioorg Med Chem, 16 (2): 739-45. [PMID:17964793]
20. Luzzani F, Glässer A. (1981) Differential binding in vitro to glucocorticoid receptors of deflazacort and prednisolone. Eur J Pharmacol, 76 (4): 427-30. [PMID:7327211]
21. Markham A, Keam SJ. (2019) Peficitinib: First Global Approval. Drugs, 79 (8): 887-891. [PMID:31093950]
22. Mayer L, Sandborn WJ, Stepanov Y, Geboes K, Hardi R, Yellin M, Tao X, Xu LA, Salter-Cid L, Gujrathi S et al.. (2014) Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut, 63 (3): 442-50. [PMID:23461895]
23. Mohamed MF, Klünder B, Camp HS, Othman AA. (2019) Exposure-Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection. Clin Pharmacol Ther, 106 (6): 1319-1327. [PMID:31194885]
24. Motoya S, Watanabe M, Kim HJ, Kim YH, Han DS, Yuasa H, Tabira J, Isogawa N, Arai S, Kawaguchi I et al.. (2018) Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies. Intest Res, 16 (2): 233-245. [PMID:29743836]
25. Namour F, Galien R, Van Kaem T, Van der Aa A, Vanhoutte F, Beetens J, Van't Klooster G. (2016) Safety, pharmacokinetics and pharmacodynamics of GLPG0974, a potent and selective FFA2 antagonist, in healthy male subjects. Br J Clin Pharmacol, 82 (1): 139-48. [PMID:26852904]
26. Ostrovskyi D, Rumpf T, Eib J, Lumbroso A, Slynko I, Klaeger S, Heinzlmeir S, Forster M, Gehringer M, Pfaffenrot E et al.. (2016) Tofacitinib and analogs as inhibitors of the histone kinase PRK1 (PKN1). Future Med Chem, 8 (13): 1537-51. [PMID:27572962]
27. Panés J, Sandborn WJ, Schreiber S, Sands BE, Vermeire S, D'Haens G, Panaccione R, Higgins PDR, Colombel JF, Feagan BG et al.. (2017) Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. Gut, 66 (6): 1049-1059. [PMID:28209624]
28. Panés J, Vermeire S, Lindsay JO, Sands BE, Su C, Friedman G, Zhang H, Yarlas A, Bayliss M, Maher S et al.. (2018) Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies. J Crohns Colitis, 12 (2): 145-156. [PMID:29028981]
29. Pavlidis P, Tsakmaki A, Pantazi E, Li K, Cozzetto D, Digby-Bell J, Yang F, Lo JW, Alberts E, Sa ACC et al.. (2022) Interleukin-22 regulates neutrophil recruitment in ulcerative colitis and is associated with resistance to ustekinumab therapy. Nat Commun, 13 (1): 5820. [PMID:36192482]
30. Pizzonero M, Dupont S, Babel M, Beaumont S, Bienvenu N, Blanqué R, Cherel L, Christophe T, Crescenzi B, De Lemos E et al.. (2014) Discovery and optimization of an azetidine chemical series as a free fatty acid receptor 2 (FFA2) antagonist: from hit to clinic. J Med Chem, 57 (23): 10044-57. [PMID:25380412]
31. Pérez-Jeldres T, Tyler CJ, Boyer JD, Karuppuchamy T, Yarur A, Giles DA, Yeasmin S, Lundborg L, Sandborn WJ, Patel DR et al.. (2019) Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists. Front Pharmacol, 10: 212. [PMID:30930775]
32. RIESE JA. (1957) The use of corticotropin-zinc hydroxide in the treatment of ulcerative colitis and other colonic disorders. Am J Gastroenterol, 28 (4): 452-9. [PMID:13469787]
33. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL et al.. (1999) Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology, 117 (4): 761-9. [PMID:10500056]
34. Sandborn WJ, Su C, Sands BE, D'Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W et al.. (2017) Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med, 376 (18): 1723-1736. [PMID:28467869]
35. Sands BE, Sandborn WJ, Panaccione R, O'Brien CD, Zhang H, Johanns J, Adedokun OJ, Li K, Peyrin-Biroulet L, Van Assche G et al.. (2019) Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med, 381 (13): 1201-1214. [PMID:31553833]
36. Shukla T, Sands BE. (2019) Novel Non-biologic Targets for Inflammatory Bowel Disease. Curr Gastroenterol Rep, 21 (5): 22. [PMID:31016396]
37. Smolen JS, Pangan AL, Emery P, Rigby W, Tanaka Y, Vargas JI, Zhang Y, Damjanov N, Friedman A, Othman AA et al.. (2019) Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet, 393 (10188): 2303-2311. [PMID:31130260]
38. Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER. (2009) The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther, 330 (3): 864-75. [PMID:19509315]
39. Takahashi S, Andreoletti G, Chen R, Munehira Y, Batra A, Afzal NA, Beattie RM, Bernstein JA, Ennis S, Snyder M. (2017) De novo and rare mutations in the HSPA1L heat shock gene associated with inflammatory bowel disease. Genome Med, 9 (1): 8. [PMID:28126021]
40. Taylor Meadows KR, Steinberg MW, Clemons B, Stokes ME, Opiteck GJ, Peach R, Scott FL. (2018) Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus. PLoS ONE, 13 (4): e0193236. [PMID:29608575]
41. Thorarensen A, Dowty ME, Banker ME, Juba B, Jussif J, Lin T, Vincent F, Czerwinski RM, Casimiro-Garcia A, Unwalla R et al.. (2017) Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans. J Med Chem, 60 (5): 1971-1993. [PMID:28139931]
42. Torgutalp M, Poddubnyy D. (2018) Emerging treatment options for spondyloarthritis. Best Pract Res Clin Rheumatol, 32 (3): 472-484. [PMID:31171316]
43. van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, Woody J. (1995) Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology, 109 (1): 129-35. [PMID:7797011]
44. Vermeire S, O'Byrne S, Keir M, Williams M, Lu TT, Mansfield JC, Lamb CA, Feagan BG, Panes J, Salas A et al.. (2014) Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet, 384 (9940): 309-18. [PMID:24814090]
45. Vermeire S, Sandborn WJ, Danese S, Hébuterne X, Salzberg BA, Klopocka M, Tarabar D, Vanasek T, Greguš M, Hellstern PA et al.. (2017) Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet, 390 (10090): 135-144. [PMID:28527704]
46. Voss JW, Camp HS, Padley RJ. (2015) Jak1 selective inhibitor and uses thereof. Patent number: WO2015061665. Assignee: Abbvie Inc.. Priority date: 24/10/2013. Publication date: 30/04/2015.
47. Wang M, Kussrow AK, Ocana MF, Chabot JR, Lepsy CS, Bornhop DJ, O'Hara DM. (2017) Physiologically relevant binding affinity quantification of monoclonal antibody PF-00547659 to mucosal addressin cell adhesion molecule for in vitro in vivo correlation. Br J Pharmacol, 174 (1): 70-81. [PMID:27760281]
48. Yellin M, Paliienko I, Balanescu A, Ter-Vartanian S, Tseluyko V, Xu LA, Tao X, Cardarelli PM, Leblanc H, Nichol G et al.. (2012) A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheum, 64 (6): 1730-9. [PMID:22147649]
49. Zhou H, Jang H, Fleischmann RM, Bouman-Thio E, Xu Z, Marini JC, Pendley C, Jiao Q, Shankar G, Marciniak SJ et al.. (2007) Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol, 47 (3): 383-96. [PMID:17322150]